SOLV Solventum Corp
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1964738 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY-89.8%
TTM EPS YoY-89.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin54.8%
Operating margin5.6%
Net margin1.9%
FCF margin0.0%
EBITDA margin9.6%
Returns
ROE3.2%
ROA1.1%
ROIC (approx.)4.7%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets66.1%
Debt / equity1.05x
Current ratio1.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.99x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.95B | $2.21B | $2.01B | $2.00B | $2.10B | $2.16B | $2.07B | $2.08B |
| Gross profit | $1.06B | $1.29B | $1.10B | $1.03B | $1.14B | $1.18B | $1.11B | $1.12B |
| R&D expense | $181.00M | $178.00M | $189.00M | $175.00M | $183.00M | $189.00M | $193.00M | $199.00M |
| SG&A expense | $813.00M | $927.00M | $827.00M | $759.00M | $780.00M | $772.00M | $769.00M | $784.00M |
| Operating income | $68.00M | $181.00M | $81.00M | $124.00M | $1.69B | $214.00M | $152.00M | $136.00M |
| Pretax income | -$11.00M | $108.00M | $16.00M | $58.00M | $1.51B | $103.00M | $38.00M | $13.00M |
| Income tax | $1.00M | $15.00M | $3.00M | -$5.00M | $248.00M | $13.00M | -$99.00M | -$17.00M |
| Net income | -$12.00M | $92.00M | $13.00M | $63.00M | $1.27B | $90.00M | $137.00M | $31.00M |
| EBITDA | $106.00M | $217.00M | $216.00M | $241.00M | $1.73B | $252.00M | $281.00M | $286.00M |
| EPS (basic) | -0.07 | 0.53 | 0.07 | — | 7.26 | 0.52 | 0.79 | — |
| EPS (diluted) | -0.07 | 0.53 | 0.07 | — | 7.22 | 0.51 | 0.78 | — |
| Weighted avg. shares (diluted) | 170.80M | 173.30M | 175.50M | — | 175.40M | 175.20M | 174.80M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $451.00M | $403.00M | $561.00M | $878.00M | $1.64B | $492.00M | $534.00M | $762.00M |
| Receivables | $1.36B | $1.31B | $1.06B | $1.03B | $1.02B | $1.06B | $926.00M | $1.04B |
| Inventory | $1.10B | $1.04B | $1.09B | $1.07B | $1.05B | $962.00M | $866.00M | $965.00M |
| Current assets | $3.69B | $3.74B | $3.58B | $3.86B | $4.41B | $3.21B | $3.05B | $3.25B |
| PP&E, net | $1.59B | $1.56B | $1.54B | $1.33B | $1.34B | $1.31B | $1.20B | $1.62B |
| Goodwill | $5.62B | $5.63B | $5.63B | $5.70B | $5.26B | $5.27B | $4.99B | $6.38B |
| Intangibles | $2.32B | $2.41B | $2.50B | $2.59B | $2.22B | $2.30B | $2.37B | $2.54B |
| Total assets | $14.16B | $14.24B | $14.10B | $14.29B | $13.97B | $15.07B | $14.53B | $14.46B |
| Current liabilities | $3.58B | $3.66B | $3.35B | $3.14B | $2.94B | $2.62B | $2.57B | $2.70B |
| Short-term debt | $507.00M | $506.00M | $505.00M | $0 | $0 | $0 | $100.00M | $200.00M |
| Long-term debt | $4.56B | $4.57B | $4.58B | $5.04B | $5.14B | $7.82B | $7.81B | $7.81B |
| Total debt | $5.07B | $5.08B | $5.08B | $5.04B | $5.14B | $7.82B | $7.91B | $8.01B |
| Total liabilities | $9.36B | $9.44B | $9.13B | $9.24B | $8.99B | $11.43B | $11.27B | $11.50B |
| Shareholders' equity | $4.80B | $4.80B | $4.97B | $5.05B | $4.99B | $3.65B | $3.26B | $2.96B |
| Net debt | $4.62B | $4.68B | $4.52B | $4.16B | $3.50B | $7.32B | $7.38B | $7.25B |
| Shares outstanding | 169.96M | 170.11M | 173.53M | 173.49M | 173.44M | 173.39M | 173.01M | 172.79M |
| Cash flow statement | ||||||||
| Operating cash flow | $177.00M | $227.00M | -$189.00M | $95.00M | $76.00M | $169.00M | $29.00M | $219.00M |
| Capital expenditure | $80.00M | $83.00M | $84.00M | $63.00M | $97.00M | $110.00M | $109.00M | $127.00M |
| Free cash flow | $97.00M | $144.00M | -$273.00M | $32.00M | -$21.00M | $59.00M | -$80.00M | $92.00M |
| Investing cash flow | -$80.00M | -$87.00M | -$77.00M | -$745.00M | $3.77B | -$110.00M | -$114.00M | -$127.00M |
| Financing cash flow | -$51.00M | -$300.00M | -$50.00M | -$115.00M | -$2.69B | -$110.00M | -$139.00M | -$104.00M |
| Depreciation & amortization | $38.00M | $36.00M | $135.00M | $117.00M | $37.00M | $38.00M | $129.00M | $150.00M |
| Stock-based compensation | $42.00M | $38.00M | $51.00M | $37.00M | $41.00M | $34.00M | $49.00M | $25.00M |
| Share buybacks | $48.00M | $288.00M | $67.00M | — | $0 | $0 | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.